RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis - Concepedia

Concepedia

Publication | Open Access

RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis

DOI Full Paper Access

18

Citations

16

References

2015

Year

Adam M. Kruszewski, Gautam G. Rao, Alexandru Tatomir, Daniel Hewes, Cosmin Tegla, Cornelia Cudrici, Vingh Nguyen, Walter Royal, Christopher T. Bever, Violeta Rus,

Experimental and Molecular Pathology

Translational MedicineNeurobiology Of DiseaseAutoimmune DiseaseMedicineImmunologyPotential BiomarkerBrain-immune InteractionNeuroprotectionNeurologyMultiple SclerosisNeuroimmunologyGlatiramer AcetateNeuroinflammation

References

	Year	Citations

Page 1

Page 1